Anjeso is the first intravenous (IV) formulation of meloxicam for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
Before Anjeso, Meloxicam was already available as oral tablet, oral capsule, and orally disintegrating tablet.
Anjeso is a nonsteroidal anti-inflammatory drug (NSAID). It is a sterile opaque, pale-yellow, aqueous dispersion containing the active pharmaceutical ingredient meloxicam for intravenous administration.
The active ingredient meloxicam is a long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis.
Approval date: 20 Feb. 2020
Brand name: Anjeso
Innovator: Baudax
Route and Dosage form: Intravenous Injection
Strengths: 30MG/ML
Indication: NSAID indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
Excipients employed in Anjeso: Sodium deoxycholate (deoxycholic acid), Sucrose, and water for injection.
Prescribing information: Available here
Orange book information: Available here
No comments:
Post a Comment